Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

• Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial
  

NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO and EPSOLAY, today announced it will host a virtual KOL event on Wednesday, December 6, 2023 at 12:00 PM ET. To register, click here.

The event will feature Julie Breneiser (Executive Director, Gorlin Syndrome Alliance) and Ervin Epstein Jr., MD (Co-Founder of PellePharm Inc.), who will discuss the significant disease burden of Gorlin syndrome patients and lack of effective therapies. Gorlin syndrome is a rare genetic disorder associated with growth of multiple basal cell carcinomas.

The event will also focus on the therapeutic potential of SGT-610 (patidegib gel), a new hedgehog inhibitor (HHI), in development to prevent new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome with the potential for a more favorable tolerability profile compared to approved oral HHIs. SGT-610 has been granted Orphan Drug Designation as well as Breakthrough Designation by the FDA.

Alon Seri-Levy, PhD (Co-Founder and Chief Executive Officer, Sol-Gel Therapeutics) will provide an overview of the upcoming SGT-610 Phase 3 study, including strategies intended to optimize success of the study, and insights on market potential. A live question and answer session will follow the formal presentation.

About Julie Breneiser

Julie Breneiser is the Executive Director of the Gorlin Syndrome Alliance (GSA). Prior to her position as director, Julie served as volunteer Board President for the GSA. Mrs. Breneiser and her two young adult children are affected with Gorlin syndrome, a rare genetic disorder caused by a tumor suppressant mutation that can affect every organ system. Her early career began as a Physician Assistant followed by teaching preschoolers with disabilities. Mrs. Breneiser’s work with the GSA focuses on collaboration with industry to bring new and/or potential treatments to clinical trial. She also provides individual support to affected patients and their caregivers along with educating health care providers about this rare disease. Mrs. Breneiser previously served as a consumer reviewer for the National Institutes of Health and the Department of Defense’s Congressionally Directed Medical Research Program. Mrs. Breneiser speaks nationally and internationally raising awareness about Gorlin syndrome.​